

# Global Capabilities



## Your Partner in Assay Development from Biomarker Discovery to Commercialization

We have expanded our global footprint with the addition of Singapore and China, which along with Switzerland completes our international network of labs outside of the US. In just under two decades we have built a reputation for credibility and reliability; serving the needs of the oncology, pathology, and pharmaceutical community with newly expanded services to support a global wetlab footprint.

Our test menu features over 650 tests including IHC, FISH, Flow Cytometry, Molecular, Next-Generation Sequencing, Cytogenetics, and our proprietary MultiOmyx™ technology. The breadth of our menu, coupled with the power of our consultative services provides our customers with unparalleled insight into the nature of cancer and allows our customers to expand their development journey from assay development through commercialization. Having participated in hundreds of immunotherapy and other biomarker development trials, NeoGenomics plays a vital role in improving patient care and advancing precision medicine.

## Lab Services We Offer




Anatomic Pathology



Genomics



Multiplexed IF



FISH & Flow Cytometry



CDx & IVD



Cytogenetics



Immunoassays



Data



[neogenomics.com](http://neogenomics.com)



## The Global Oncology Community's Assay Development Partner from Biomarker Discovery to Commercialization

- Proprietary MultiOmyx technology – evaluation of up to 60 biomarkers in a single slide
- Test modality offerings continue to be expanded across all our international sites. Ability to develop assays at specific sites and transfer to other sites
- Largest global provider of PD-L1 IHC testing
- Global SOPs across all locations provide greater continuity and QA
- Proven commercialization record
- Agility in project customization

### Global Value Proposition

1. Poised to support you – from planning through execution
2. Guaranteed one business day response on project inquiries
3. Customized delivery of project data that meets your specific reporting requirements
4. Proactive project management with a clear line of responsibility mitigates risks

### Global Consultation

We are proud of the collective knowledge shared amongst our scientific team. With this we are able to support the expansive range of oncology expertise needed within the industry. Consultation across the continuum of development from pre-clinical research and development through CDx commercialization is a core NeoGenomics strength.



© 2020 NeoGenomics Laboratories, Inc. All Rights Reserved.  
MultiOmyx is a trademark of NeoGenomics, Inc, which holds a license from GE HealthCare BioSciences Corp. All other trademarks are the property of their respective owners. Rev. 102020

12701 Commonwealth Dr., Suite 9  
Fort Myers, FL 33913 United States  
**Phone:** 866.776.5907  
**Fax:** 239.690.4237

31 Columbia  
Aliso Viejo, CA 92656 United States  
**Phone:** 800.720.4363  
**Fax:** 949.425.5865

7256 S. Sam Houston Pkwy W., Suite 300  
Houston, TX 77085 United States  
**Phone:** 800.720.4363 / 713.528.4363  
**Fax:** 713.668.3565

NeoGenomics Laboratories, Inc.  
4570 Executive Drive., Suite 250  
San Diego, CA 92121  
**Phone:** 949-445-7300 x5056

NeoGenomics Europe, S.A.  
A-One Business Center  
Bâtiment A5, 2nd Floor  
Z.A. La Pièce/Route de l'Etraz 1  
1180 Rolle, Switzerland  
**Phone:** +41.21.721.06.00  
**Fax:** +41 (0)21 826 00 73

NeoGenomics Singapore Pte. Ltd.  
61 Science Park Road, #02-11  
Singapore 117525  
**Phone:** +65-69115202

Suzhou NeoGenomics  
Pharmaceutical Research Co., Ltd  
Building 6, Block 19, Yong'An Road  
Huguan Industrial Park,  
Suzhou New District, China